News

not found

New revolutionary technique to 3D-print multiple drugs in single tablet

Think of a future where every pill you take is tailor-made just for you. Scientists at the University of Nottingham are leading the way with an amazing new technology. They’re using 3D printing to create tablets containing multiple drugs and programmed to release them at specific times. It’s like having your own custom-made medicine. This development, led by Dr. Yinfeng He from the University’s Centre for Additive Manufacturing and Professor Felicity Rose from the School of Pharmacy, has the potential to revolutionize how we treat diseases. Printing on demand: How it works The research details a novel 3D printing technique called Multi-Material InkJet 3D Printing (MM-IJ3DP). With this method, scientists can fabricate customized tablets with intricate internal structures. These structures are important because they help give you the right medicine at the right time. The secret lies in a specially formulated ink that contains light-sensitive molecules. During the printing process, these molecules solidify upon exposure to ultraviolet light, forming a water-soluble framework within the tablet.By carefully designing these internal structures, researchers can control the rate at which the drugs are released. A single pill for complex regimens This targeted release system opens doors for a future of simplified medication schedules. MM-IJ3DP enables the incorporation of multiple drugs into a single tablet. This eliminates the hassle of managing complex regimens that require taking several pills at different times. “This is an exciting step forwards in the development of personalized medication,” explains He.  “This breakthrough not only highlights the potential of 3D printing in revolutionizing drug delivery but also opens up new avenues for the development of next-generation personalized medicines,” he added. Overcoming challenges for widespread adoption While the potential of MM-IJ3DP is undeniable, there are still hurdles to overcome. The current technology requires the development of more ink formulations that can accommodate a wider range of medications. Researchers are actively addressing this challenge to pave the way for broader application of the technique. “The ongoing research aims to refine these aspects, enhancing the feasibility of MM-IJ3DP for widespread application,” says Professor Ricky Wildman, another project collaborator. Precise dosing for optimal treatment This technology holds particular promise for conditions where timing and dosage accuracy are critical. MM-IJ3DP provides a solution for medications that require controlled release at specific intervals throughout the day. The ability to print large batches (demonstrated by creating 56 pills in a single run) further strengthens the case for MM-IJ3DP as a viable method for large-scale production of personalized medicines. A brighter future for medication adherence Rose emphasizes the impact this technology can have on medication adherence, a significant issue in healthcare. “Up to 50% of people in the UK alone don’t take their medicines correctly,” she reveals.  “A single pill approach would simplify taking multiple medications at different times and this research is an exciting step towards that,” she added. This new 3D-printed pill method could change everything. It would make medicine schedules fit you better and treat chronic diseases much better. It’s like a peek into a future where medicine is all about you.

  • 22 May, 11:42
  • Read more
not found

WHO updates list of drug-resistant bacteria

The World Health Organization (WHO) today released its updated Bacterial Priority Pathogens List (BPPL) 2024, featuring 15 families of antibiotic-resistant bacteria grouped into critical, high and medium categories for prioritization. The list provides guidance on the development of new and necessary treatments to stop the spread of antimicrobial resistance (AMR). AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to medicines, making people sicker and increasing the risk of disease spread, illness and deaths. AMR is driven in large part by the misuse and overuse of antimicrobials. The updated BPPL incorporates new evidence and expert insights to guide research and development (R&D) for new antibiotics and promote international coordination to foster innovation. “Antimicrobial resistance jeopardizes our ability to effectively treat high burden infections, such as tuberculosis, leading to severe illness and increased mortality rates," said Dr Jérôme Salomon, WHO's Assistant Director-General for Universal Health Coverage, Communicable and Noncommunicable Diseases. The WHO BPPL 2024 includes the following bacteria: Critical priority: Acinetobacter baumannii, carbapenem-resistant; Enterobacterales, third-generation cephalosporin-resistant; and  Enterobacterales, carbapenem-resistant; Mycobacterium tuberculosis, rifampicin-resistant (included after an independent analysis with parallel tailored criteria, and subsequent application of an adapted multi-criteria decision analysis matrix).    High priority: Salmonella Typhi, fluoroquinolone-resistant Shigella spp., fluoroquinolone-resistant Enterococcus faecium, vancomycin-resistant Pseudomonas aeruginosa, carbapenem-resistant Non-typhoidal Salmonella, fluoroquinolone-resistant Neisseria gonorrhoeae, third-generation cephalosporin- and/or fluoroquinolone-resistant Staphylococcus aureus, methicillin-resistant Medium priority:  Group A streptococci, macrolide-resistant Streptococcus pneumoniae, macrolide-resistant Haemophilus influenzae, ampicillin-resistant Group B streptococci, penicillin-resistant

  • 20 May, 10:00
  • Read more
not found

AstraZeneca withdrawing Covid vaccine worldwide

The Oxford-AstraZeneca Covid vaccine is being withdrawn worldwide, months after the pharmaceutical giant admitted for the first time in court documents that it can cause a rare and dangerous side effect. The vaccine can no longer be used in the European Union after the company voluntarily withdrew its “marketing authorisation”. The application to withdraw the vaccine was made on March 5 and came into effect on Tuesday. Similar applications will be made in the coming months in the UK and in other countries that had approved the vaccine, known as Vaxzevria. The decision to withdraw it brings to an end the use of the jab, which was heralded by Boris Johnson as a “triumph for British science” and credited with saving more than six million lives. AstraZeneca said the vaccine was being removed from markets for commercial reasons. It said the vaccine was no longer being manufactured or supplied, having been superseded by updated vaccines that tackle new variants.  Vaxzevria has come under intense scrutiny in recent months over a very rare side effect, which causes blood clots and low blood platelet counts. AstraZeneca admitted in court documents lodged with the High Court in February that the vaccine “can, in very rare cases, cause TTS”. TTS – which stands for Thrombosis with Thrombocytopenia Syndrome – has been linked to at least 81 deaths in the UK as well as hundreds of serious injuries. AstraZeneca is being sued by more than 50 alleged victims and grieving relatives in a High Court case. But AstraZeneca has insisted the decision to withdraw the vaccine is not linked to the court case or its admission that it can cause TTS. It said the timing was pure coincidence.

  • 10 May, 09:00
  • Read more
Нажмите на кнопку ниже, чтобы прослушать текст Powered by GSpeech